Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health
Open accessThe DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index; 7 of the 42 sources its claims cite were checked for support.
Abstract
Background: Benzodiazepines and non-benzodiazepine hypnotics (z-drugs) are commonly prescribed for their anxiolytic and hypnotic properties, though they can also be misused. In studies examining the epidemiology of prescription drug misuse, these medication classes are commonly combined, rendering inadequate knowledge of their patterns of misuse. The objective of this study was to characterize the population prevalence, conditional dependence, and sociodemographic and clinical correlates of the misuse of benzodiazepines and z-drugs. Methods: Data from the National Survey on Drug Use and Health from 2015 to 2019 were used to estimate population-level prevalence and characteristics of benzodiazepine and z-drug misuse. Groups were derived based on past-year misuse of benzodiazepines alone, z-drugs alone, or both drug types. Unadjusted regression analyses were used to compare groups on characteristics of interest. Results: prescription or misuse was common; however, only 2% of the population was estimated to have misused a benzodiazepine in the past year, and less than 0.5% misused z-drugs. People who misused only z-drugs were generally older, more likely to have health insurance, more educated, and had less severe psychiatric symptoms. This group was also more likely to report misuse to cope with sleep difficulty. Although concurrent substance use was highly prevalent in all groups, people who misused z-drugs alone generally reported less concurrent substance use than the other groups. Conclusion: The misuse of z-drugs is less common than benzodiazepines, and people who misuse only z-drugs appear to generally have lower clinical severity. Nonetheless, a substantial subgroup of people exposed to z-drugs report concurrent, past-year use of other substances. Further research on z-drug misuse, including consideration of whether it should be grouped with other anxiolytic/hypnotic drugs, is needed.
Overview
CoChat Summary
## TL;DR
Using NSDUH data from 2015–2019 (n = 282,768), this study found that past-year misuse was much less common for z-drugs than for benzodiazepines, but z-drug misuse still affected a notable minority of exposed users. People who misused only z-drugs tended to be older and less clinically severe than those who misused benzodiazepines, while concurrent substance use was common across all groups.
## Key findings
- In the full population, estimated past-year misuse was 2% for benzodiazepines and <0.4% for z-drugs; among people exposed to these medications, misuse was 17.7% for benzodiazepines and 9.2% for z-drugs.
- Past-year exposure itself was common: 13.7% of the population used either medication class, including 11.4% who used or misused benzodiazepines and 4% who used or misused z-drugs.
- Sedative/anxiolytic use disorder was reported by 2.3% of people who used benzodiazepines and 2.1% of people who used z-drugs; among those who misused them, 12.3% of benzodiazepine misusers and 13.6% of z-drug misusers met criteria for a disorder.
- The combined misuse group had the highest clinical severity: suicidal ideation (24.9%), suicide plan (11%), and suicide attempt (7%), compared with benzodiazepine-only misuse (18.3%, 7.3%, 3.7%) and z-drug-only misuse (10.6%, 3.4%, 0.9%).
- Concurrent substance use was highest in the combined group, with an estimated mean of 6.03 drugs, versus 4.32 in the benzodiazepine-only group and 3.19 in the z-drug-only group.
- For z-drug-only misuse, the dominant motive was sleep: over 88% reported this motive; the paper also reports that sleep-motived misuse was more common than in the benzodiazepine-only group (OR = 13.80, 95% CI 9.98–19.08).
## Methods
- Secondary analysis of the National Survey on Drug Use and Health (NSDUH) from 2015–2019, a U.S. annual multistage probability sample; aggregated sample size was 282,768 participants.
- Defined three past-year groups based on use/misuse: benzodiazepines only, z-drugs only, and both; examined prevalence of misuse and sedative/anxiolytic use disorder, plus sociodemographic, clinical, other substance use, and motive variables.
- Used unadjusted regression analyses, including multinomial logistic regression, with survey design accounted for and false discovery rate correction for multiple testing.
## Limitations
- The authors state the analysis inherits general NSDUH limitations, including inability to generalize to un- or underrepresented groups such as incarcerated and un-housed people, plus sampling biases.
- The paper notes several variables were not assessed in NSDUH or not available over a past-year timeframe; specifically, this limited examination of co-use of substances, frequency of misuse, and source of prescription medications for misuse.
- The paper says responses for some outcomes combined tranquilizers and sedatives, making it hard to isolate unique effects of benzodiazepines versus z-drugs; this is especially important for the combined-use group.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
5 Valid · 0 Not valid · 19 Not checked · 41 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Z-drugs bind preferentially to GABAA receptors containing α1-subunits, which modulate sedation and amnesia (25, 26).”
§ Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health > 4. Discussion
What the sources say
- Supportedcites [25] Gunja, 2013, The clinical and forensic toxicology of Z-drugs, J Med Toxicol source
The Pharmacology section states that 'Sedation and amnesia are mediated through the α1 subunit' and that BZ1 receptors contain α1β1-3γ2 subunits, with Z-drugs showing 'differential binding' to GABA-A isoforms. The same section then attributes preferential/selective α1 action to each Z-drug individually: zolpidem 'mediates its effects largely through activation of the α1-containing GABA A (BZ1) receptor', zopiclone 'shows preferential agonist activity at the α1 subunit', and zaleplon 'exerts its effects through selective binding at BZ1 receptors (α1 subunit)'. Together these support both halves of the paraphrase (preferential α1 binding and α1-mediated sedation/amnesia). (LLM, conf=0.90)
- Partly supportedcites [26] Rowlett, 2005, Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
Our copy supports the binding and sedation halves: the Abstract states that zolpidem 'shows preferential binding to GABAA receptors containing alpha1-subunits', and the Discussion (and Introduction) state that sedative properties 'involve the alpha1GABAA subtype primarily'. Two parts are not supported: (1) the paper addresses only zolpidem, not Z-drugs as a class; (2) no amnesia/memory effect is attributed to alpha1 anywhere — the Introduction instead assigns memory processes to the alpha5 subtype ('Receptors containing alpha5-subunits ... might play a role in memory processes'), and the study measured anxiolytic, sedative, motor, discriminative-stimulus and reinforcing effects only, with no memory task. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of note, the sedative/anxiolytic use disorder rates among those with any benzodiazepine use reported herein were similar to those previously estimated using 2015–2016 NSDUH data (9)”
§ Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health > 4. Discussion
What the sources say
- Supportedcites [9] Blanco, 2018, Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States., J Clin Psychiatry. source
Blanco et al. (2018) is exactly the prior 2015–2016 NSDUH-based estimate the citing sentence credits it for: the Results (Prevalence section) and Abstract RESULTS report that among benzodiazepine users, 1.5% (95% CI=1.26%–1.72%) had benzodiazepine use disorders, based on 102,000 adults from the 2015–2016 NSDUH. The METHODS > Measures section shows these 'benzodiazepine use disorders' are operationalized as past-year DSM-based tranquilizer use disorders or sedative use disorders among benzodiazepine misusers, i.e. the sedative/anxiolytic use disorder category the citing paper names. The 'were similar to' comparison is the citing authors' own finding ('reported herein') and is not judged here. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The prevalence of misuse may be attributable—at least in part—to the high levels of population exposure to these drugs via prescription (8).”
§ Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health > 1. Introduction
What the sources say
- Partly supportedcites [8] Bachhuber, 2016, Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013., Am J Public Health. sourceExperimental — accuracy not yet measured
Our copy firmly documents the claim's premise — the population-exposure side: the Abstract/Results report the percentage of US adults filling a benzodiazepine prescription rising from 4.1% (1996) to 5.6% (2013) and the quantity filled more than tripling to 3.6 kg lorazepam equivalents per 100 000 adults (Abstract; Results). But the paper never addresses the prevalence of benzodiazepine (or z-drug) misuse: its outcome is fatal overdose, and the Discussion's only nod to non-prescribed supply is the hedged mechanism 'people at high risk for fatal overdose may be obtaining diverted benzodiazepines... The proportion of fatal overdoses involving diverted versus prescribed benzodiazepines is unknown' (Discussion). The attribution of misuse prevalence to prescription exposure, and any extension to z-drugs, is therefore not supported by this source (z-drugs appear in our copy only in a reference title on drug metabolism). (LLM, conf=0.68)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These differences are consistent with the mechanism of action and pharmacological properties of benzodiazepines and z-drugs.”
§ Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health > 4. Discussion
What the sources say
- Supportedcites [25] Gunja, 2013, The clinical and forensic toxicology of Z-drugs, J Med Toxicol source
The part attributed to this source — the mechanism of action and pharmacological properties of benzodiazepines versus Z-drugs — is stated directly in our copy: the Pharmacology section describes benzodiazepines binding non-selectively to ω1(BZ1)/ω2(BZ2) with anxiolysis via α2/α3 and sedation/amnesia via α1, while Z-drugs bind the same site with differential isoform affinity (zolpidem a potent sedative-hypnotic with minimal anxiolytic efficacy; zaleplon selective at α1; zopiclone longest duration), and the Introduction/Pharmacokinetics sections add their shorter half-lives, preserved sleep architecture and lesser residual effects. The inference that these properties explain differences in users' motives is the citing authors' own conclusion and is not attributed content, so nothing in the sentence exceeds what the source reports. Note the review explicitly states it does not examine purported benefits of Z-drugs over benzodiazepines or hypnotic clinical efficacy, but it does supply the pharmacology/MOA details cited. (LLM, conf=0.85)
- Partly supportedcites [26] Rowlett, 2005, Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
Our copy does supply the pharmacological half of the sentence: the Introduction/Abstract (p.1) states that benzodiazepines act by allosterically binding GABAA receptors at the γ2/α1, α2, α3 or α5 interface, and that zolpidem is the α1-preferring compound, while the Discussion (p.1) and Results map subtype action onto anxiolytic, sedative, ataxic, discriminative-stimulus and reinforcing effects — including that 'zolpidem maintained the highest levels of self-administration of any benzodiazepine-type drug tested.' What the source does not support is the bridging assertion about users' motives: the paper contains no human data on reasons for taking these drugs (its abuse-related measures are monkey drug discrimination and progressive-ratio self-administration), it treats only zolpidem rather than z-drugs as a class, and its subtype-effect attributions are explicitly hedged ('α1GABAA receptor subtype might be critically involved'; α1 stimulation 'sufficient, but not necessary' for abuse potential), so it does not state that motivational differences follow from this mechanism. (LLM, conf=0.68)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 4% using or misusing a z-drug.”
§ Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health > 3. Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
28 more claims
Create a free account to see all 65 claims and to verify the 35 references still open.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When insomnia is not properly diagnosed and managed, and hypnotics are used beyond the recommended duration—particularly with the development of tolerance that leads to dose escalation or increased frequency of use—the risk of substance use disorder rises significantly.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The prevalence of Z-drug use disorder may be higher in women, though the findings are inconsistent across studies.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [45]
Experimental — accuracy not yet measured
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“A false discovery rate procedure (22) adjusted the p-value for multiple testing for each outcome.”
MethodScreening for serious mental illness in the general population
Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gfroerer, J. C., Hiripi, E., Howes, M. J., Normand, S.-L. T., Manderscheid, R. W., Walters, E. E., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.184 · Cited by 5,692 · cited 1×
“Participants received a score from 0 to 24, with higher scores reflecting greater psychiatric distress (20).”
BackgroundDeveloping the World Health Organization Disability Assessment Schedule 2.0
Üstün, T. B., Chatterji, S., Kostanjsek, N., Rehm, J., Kennedy, C., Epping-Jordan, J., Saxena, S., von Korff, M., & Pull, C. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.09.067231 · Cited by 1,851 · cited 1×
“The World Health Organization Disability Assessment Schedule (WHODAS) was used to assess impaired functioning in various domains such as cognition, mobility, and self-care (21).”
MethodPolydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703 · cited 1×
“Previous research has also demonstrated that benzodiazepines have greater misuse liability among those with histories of alcohol use disorder (23) and increase the reinforcing effects of opioids when they are taken in combination (24), consistent with our findings that those with benzodiazepine misuse had higher rates…”
ResultIncreasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013
Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016) · American Journal of Public Health · doi:10.2105/ajph.2016.303061 · Cited by 531
The epidemiology of benzodiazepine misuse: A systematic review*
Votaw, V. R., Geyer, R., Rieselbach, M. M., & McHugh, R. K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.033 · Cited by 479
Self-citationPolysubstance use: diagnostic challenges, patterns of use and health
Connor, J. P., Gullo, M. J., White, A., & Kelly, A. B. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000069 · Cited by 461
Hajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404
Neural bases for addictive properties of benzodiazepines
Tan, K. R., Brown, M., Labouèbe, G., Yvon, C., Creton, C., Fritschy, J.-M., Rudolph, U., & Lüscher, C. (2010) · Nature · doi:10.1038/nature08758 · Cited by 397
Research works printed but not linked: 5
- 2020, 2019 National Survey on Drug Use and Health Detailed Tables.
- Hughes, 2016, Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health., NSDUH Data Rev., 9, 1
- 1994, Diagnostic and statistical manual of mental disorders.
- 2020, 2019 National Survey on Drug Use and Health Public Use File Codebook.
- 2020, 2020 National Survey of Drug Use and Health (NSDUH) Releases.
Cited by
Targeting Sleep Physiology to Modulate Glymphatic Brain Clearance
van Hattem, T., Verkaar, L., Krugliakova, E., Adelhöfer, N., Zeising, M., Drinkenburg, W. H. I. M., Claassen, J. A. H. R., Bódizs, R., Dresler, M., & Rosenblum, Y. (2024) · Physiology · doi:10.1152/physiol.00019.2024 · Cited by 75
Goudman, L., Moens, M., & Pilitsis, J. G. (2023) · Anesthesiology · doi:10.1097/aln.0000000000004863 · Cited by 18
“, 27 and despite the misuse and dependency problems with benzo-diazepines 28 and neuropathic mood agents, 29 prevalence of these classes of pain medication is still high in the year 2022, in both men and women.”
BackgroundLomachinsky, V., Brooks, J. D., Donahue, M. A., Sun, S., Hsu, J., Price, M., Blacker, D., Schwamm, L. H., Newhouse, J. P., Haneuse, S., et al. (2024) · Stroke · doi:10.1161/strokeaha.124.047257 · Cited by 11
“8 Changes in Medicare Part D in 2013 allowed for benzodiazepine coverage and may have further contributed to this issue.”
Bushnell, G., Lloyd, K., Olfson, M., Gerhard, T., Keyes, K. M., Cerdá, M., & Hasin, D. S. (2025) · Addiction · doi:10.1111/add.16749 · Cited by 13
“SHA misuse and SHA-UDs are associated with other substance use and other substance use disorders [3, 19, 26, 27].”
Glancy, M., Palmateer, N. E., Yeung, A., Hickman, M., Macleod, J., Bishop, J., Barnsdale, L. R., Trayner, K. M. A., Priyadarshi, S., Wallace, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116028 · Cited by 14
Metadata
- Authors
- McHugh, R. K., Votaw, V. R., Trapani, E. W., & McCarthy, M. D.
- Affiliations
- Harvard University (US)
- University of New Mexico (US)
- McLean Hospital (US)
- Corresponding author
- McHugh, R. Kathryn
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-03-09
- Volume
- 14
- Pages
- 1129447-1129447
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC10033696
- OpenAlex
- W4323666238
- Cited by
- 38
- References
- 37
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 11 · 2023: 1
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute on Drug Abuse
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- Z-drugs, benzodiazepine misuse, prescription drug misuse, non-benzodiazepine hypnotics, prevalence, sociodemographic correlates, psychiatric symptoms, sleep disorders, concurrent substance use, National Survey on Drug Use and Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health. https://app.cochat.ai/papers/10.3389/fpsyt.2023.1129447
- The paper
- McHugh, R. K., Votaw, V. R., Trapani, E. W., & McCarthy, M. D. (2023). Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1129447
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.